Nav: Home

A new piece to the puzzle sheds light on how UHRF1 regulates gene activity

November 06, 2018

Epigenetic changes often play an important role in cancer, because they cause the genetic material to be read incorrectly at certain locations. Genes that are especially critical are those that control the growth and death of cells. Scientists at Helmholtz Zentrum München have now discovered new details about the UHRF1 protein. UHRF1 catalyses particular steps that are required for marking DNA with epigenetic modifications that suppress parts of the genome. As reported in Molecular Cell, the molecule may serve as a target for drug therapies because it is produced at elevated levels in cancer cells.

All the cells in our body have the same complement of genes yet perform entirely different functions. This is because genes are read differently depending on the type of cell in which they occur. Gene activity is regulated not only at the level of the DNA sequence but also at the epigenetic level by a variety of chemical modifications made to DNA and histones. "Histones are proteins that 'package' the DNA strands in the nucleus into chromosomes. But they also play an important role in controlling gene expression", says Prof. Dr. Robert Schneider, Director of the Institute of Functional Epigenetics (IFE) at Helmholtz Zentrum München. Together with other proteins, DNA molecules and histones form chromatin. This constitutes a chemical method for condensing genetic information within the small space of the cell nucleus. Very little is known about these regulatory processes that are the focus of the research at IFE.

UHRF1: a molecule controls key steps in DNA methylation

Researchers know, however, that the protein UHRF1 (Ubiquitin-like, containing PHD and RING finger domains) plays an important role in the methylation of DNA strands. Methyl tags are chemical modifications to a DNA molecule that do not alter the genetic code, i.e. the sequence of bases of the DNA. However, they affect the activity of genes encoded in the base sequence. Methylation of DNA molecules usually acts to repress gene transcription.

UHRF1 controls DNA methylation by ensuring that an enzyme which attaches methyl groups to DNA can bind to newly formed chromatin. To accomplish this task, UHRF1 must first bind to newly formed chromatin itself and, in a second step, transfer an ubiquitin molecule (a small protein that alters the properties of other proteins) to a histone protein. To this end, UHRF1 uses various protein domains, regions with special three-dimensional structures and functions in the same molecule.

"It was not previously known exactly how this works," says Dr. Till Bartke, Deputy Director of the IFE, who supervised the study. Together with his colleague Dr. Benjamin Foster (post-doctoral researcher at the IFE), he has applied various methods in a bid to shed light on this ubiquitin-transfer step, including chemical crosslinking of molecules, mass spectroscopic studies and the use of recombinant chromatin molecules that were modified with methyl groups. "We found that an ubiquitin-like domain (UBL) must be present to transfer ubiquitin molecules", Bartke says. This is a special structural element involved in rearrangements of UHRF1 after it has bound to chromatin. In collaboration with a research group led by Dr. Sebastian Bultmann at Ludwig-Maximilians University Munich, the researchers were also able to show that the UBL domain is required for the methylation of DNA in cells.

"Our analysis of the enzymatic mechanism of UHRF1 reveals an unexpected function of the UBL domain and defines a new role of this domain in DNA methylation," the scientist explains. Because other groups have found elevated concentrations of UHRF1 in several cancers, including lung and colorectal cancer, the protein, he believes, is well-suited as a target for future therapies.
-end-
Further Information

Original Publication:


Foster, B. M. et al. (2018): Critical role of the UBL domain in stimulating the E3 ubiquitin ligase activity of UHRF1 toward chromatin. Molecular Cell, DOI: 10.1016/j.molcel.2018.09.028

As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en

The Institute of Functional Epigenetics is interested in how genes are packaged within the nucleus of a cell. The focus is on the so-called "histone proteins" on which the DNA strands are wound and that can determine whether a gene can be read or not. In addition, we are examining the connections between common diseases and distortions in DNA packing. We utilize cutting edge methods that enable us to follow changes of these processes even in individual cells. http://www.helmholtz-muenchen.de/ife/index.html

Contact for the media:

Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - E-mail: presse@helmholtz-muenchen.de

Scientific Contact at Helmholtz Zentrum München:

Dr. Till Bartke, Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Functional Epigenetics, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 1553, E-mail: till.bartke@helmholtz-muenchen.de

Helmholtz Zentrum München - German Research Center for Environmental Health

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...